Login / Signup

Comparative anticonvulsant activity of the GABAkine KRM-II-81 and a deuterated analog.

Xingjie PingMichelle J MeyerNicolas M ZahnLalit K GolaniDishary SharminKamal P PandeySepideh RevanianPrithu MondalXiaoming JinLeggy A ArnoldRok CerneJames M CookBranka DivovićMiroslav M SavićArnold LippaJodi L SmithJeffrey M Witkin
Published in: Drug development research (2023)
A series of imidazodiazepines has been developed that possess reduced sedative liabilities but retain efficacy in anticonvulsant screening models. The latest of these compounds, (5-(8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazole[1,5-α][1,4]diazepin-3-yl) oxazole known as KRM-II-81) is currently awaiting advancement into the clinic. A deuterated structural analog (D5-KRM-II-81) was made as a potential backup compound and studied here in comparison to KRM-II-81. In the present study, both compounds significantly prevented seizures in mice induced by 6 Hz (44 mA) electrical stimulation without significantly altering motoric function on a rotarod after intraperitoneal administration. Both compounds also significantly prevented clonic seizures, tonic seizures, and lethality induced by pentylenetetrazol in mice when given orally. D5-KRM-II-81 had a slightly longer duration of action against clonic and tonic seizures than KRM-II-81. Oral administration of 100 mg/kg of either KRM-II-81 or D5-KRM-II-81 was significantly less disruptive of sensorimotor function in mice than diazepam (5 mg/kg, p.o.). The present report documents that D5-KRM-II-81 represents another in this series of imidazodiazepines with anticonvulsant activity at doses that do not impair sensorimotor function.
Keyphrases
  • primary care
  • type diabetes
  • spinal cord injury
  • risk assessment
  • high fat diet induced
  • insulin resistance
  • functional connectivity